Company Overview and News

6
Portfolio PitFall #2: Holding Losers

2018-07-16 seekingalpha - 1
Superior returns are not solely achieved by finding massive winners, they're realized by letting go of the losers that are a drag on the portfolio.
SBGL.WI UPL UPLMQ TIS

70
Overview Of Some Recent Bankrupt Companies

2018-07-16 seekingalpha - 1
The effective recovery for "old" Ulra Petroleum shareholders has plunged to just a token $0.10 per share.
UPL BLT JCP BHPBF PJT WMLP WLBA XCOOQ SHLD XCO EGC BONTQ BHP SDRL BBL XCOO BHP UPLMQ BONT BHPLF

7
Implied Volatility Surging for Ultra Petroleum (UPL) Stock Options

2018-07-16 zacks
Investors in Ultra Petroleum Corp. (UPL - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 17, 2018 $2.50 Call had some of the highest implied volatility of all equity options today.
UPL GTT KRYS UPLMQ

15
Don't Underscore This REIT Known As CORR

2018-07-16 seekingalpha
CORR has proven that the revenue stream is reliable, even in periods of distress, as long as the assets are critical to the upstream operators.
HIFR UPL XOM UNIT LMRK EGC EXXIQ EXIXQ ZEE MS CCI HASI EEXXQ EXXI CANIF SRG UPLMQ

4
UPL / Ultra Petroleum Corp. 8-K (Current Report)

2018-07-12 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
UPL

11
Avis Budget Group Sees Hammer Chart Pattern: Time to Buy?

2018-07-03 zacks
Avis Budget Group, Inc. (CAR - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because CAR recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
GOOS UPL ABX AXTA UPLMQ CAR ABX

1
Ultra Petroleum (UPL) Shares March Higher, Can It Continue?

2018-07-02 zacks - 1
Investors certainly have to be happy with Ultra Petroleum Corp. (UPL - Free Report) and its short-term performance. After all, the stock has jumped by 39.8% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for UPL?
UPL UPLMQ

16
UPL / Ultra Petroleum Corp. 8-K (Current Report)

2018-06-14 sec.gov - 16
upl-8k_20180608.htm UNITED STATES
UPL

2
Ultra Petroleum (UPL) Down 2.5% Since Earnings Report: Can It Rebound?

2018-06-11 zacks - 1
It has been about a month since the last earnings report for Ultra Petroleum Corp. (UPL - Free Report) . Shares have lost about 2.5% in that time frame.
HAWLN UPL HSC HAWLM HAWLL HAWLI UPLMQ HAWEL HAWEN HAWEM

21
Adversity Is Bitter, But Its Uses May Be Sweet

2018-06-05 seekingalpha
CORR has become a battle-tested REIT that is now better prepared to scale into a safer investment platform.
HIFR UPL XOM LMRK EEXXQ EXXI CANIF EGC EXXIQ EXIXQ ZEE UPLMQ MS HASI

11
UPL / Ultra Petroleum Corp. 8-K (Current Report)

2018-06-01 sec.gov - 11
upl-8k_20180531.htm UNITED STATES
UPL

6
How New Sanctions on Iran Could Affect Crude Oil Prices

2018-05-30 marketrealist
On May 8, President Trump announced that the United States is exiting the Iran nuclear pact. Trump now plans to impose new sanctions on Iran. On May 21, US Secretary of State Mike Pompeo announced a list of demands for Iran. The demands are a prerequisite for any new agreement. He highlighted that all uranium enrichment activity must stop. Pompeo also said that all support activities for militants in the Middle East should stop.
UPL CVI UPLMQ

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

19h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

19h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

21h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to UPL / Ultra Petroleum Corp. on message board site Silicon Investor.

I need to quintuple $20,000 I need to quintuple $20,000 I need to quintuple $20,000 Ultra Petroleum (UPL) Ultra Petroleum (UPL) Ultra Petroleum (UPL)
Financialsense (FSO) - Jim Puplava forum Financialsense (FSO) - Jim Puplava forum Financialsense (FSO) - Jim Puplava forum Ultra Petroleum Corp (UPL) Ultra Petroleum Corp (UPL) Ultra Petroleum Corp (UPL)
Duplicate Duplicate Duplicate SCS Solars Computing Systems (Duplicate) SCS Solars Computing Systems (Duplicate) SCS Solars Computing Systems (Duplicate)
Making Couplets for Fun Making Couplets for Fun Making Couplets for Fun Unwired Planet (www.uplanet.com) Unwired Planet (www.uplanet.com) Unwired Planet (www.uplanet.com)
BFLYand XCMC will zoom in next couple of days BFLYand XCMC will zoom in next couple of days BFLYand XCMC will zoom in next couple of days A COUPLE BIG MOVERS!!! A COUPLE BIG MOVERS!!! A COUPLE BIG MOVERS!!!
CUSIP: 903914208